Skip to main content
Search
Main content
Scientific reports
Published

PTPRS is a novel marker for early Tau pathology and synaptic integrity in Alzheimer's disease

Authors

Alexandre Poirier, Cynthia Picard, Anne Labonté, Isabelle Aubry, Daniel Auld, Henrik Zetterberg, Kaj Blennow, PREVENT-AD research group, Michel L Tremblay, Judes Poirier

Abstract

Sci Rep. 2024 Jun 26;14(1):14718. doi: 10.1038/s41598-024-65104-2.

ABSTRACT

We examined the role of protein tyrosine phosphatase receptor sigma (PTPRS) in the context of Alzheimer's disease and synaptic integrity. Publicly available datasets (BRAINEAC, ROSMAP, ADC1) and a cohort of asymptomatic but "at risk" individuals (PREVENT-AD) were used to explore the relationship between PTPRS and various Alzheimer's disease biomarkers. We identified that PTPRS rs10415488 variant C shows features of neuroprotection against early Tau pathology and synaptic degeneration in Alzheimer's disease. This single nucleotide polymorphism correlated with higher PTPRS transcript abundance and lower p(181)Tau and GAP-43 levels in the CSF. In the brain, PTPRS protein abundance was significantly correlated with the quantity of two markers of synaptic integrity: SNAP25 and SYT-1. We also found the presence of sexual dimorphism for PTPRS, with higher CSF concentrations in males than females. Male carriers for variant C were found to have a 10-month delay in the onset of AD. We thus conclude that PTPRS acts as a neuroprotective receptor in Alzheimer's disease. Its protective effect is most important in males, in whom it postpones the age of onset of the disease.

PMID:38926456 | PMC:PMC11208446 | DOI:10.1038/s41598-024-65104-2

UK DRI Authors

Profile picture of Henrik Zetterberg

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg